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Acid-Base and Electrolyte Teaching Case
Treatment of Severe Hyponatremia in Patients With Kidney
Failure: Role of Continuous Venovenous Hemofiltration With
Low-Sodium Replacement Fluid
Lenar Yessayan, MD, Jerry Yee, MD, Stan Frinak, MSEE, and Balazs Szamosfalvi, MD
Patients with hypervolemic hyponatremia and kidney failure pose a special therapeutic challenge. Hemodialysis to correct volume overload, azotemia, and abnormal electrolyte levels will result in rapid correction of
serum sodium concentration and place the patient at risk for osmotic demyelination syndrome. We present a
patient with acute kidney injury and severe hypervolemic hypotonic hyponatremia (serum sodium , 100 mEq/L)
who was treated successfully with continuous venovenous hemofiltration. This teaching case illustrates the
limitations of hemodialysis and demonstrates how to regulate the sodium correction rate by single-pool sodium
kinetic modeling during continuous venovenous hemofiltration. Two methods to adjust the replacement fluid to
achieve the desired sodium concentration are outlined.
Am J Kidney Dis. 64(2):305-310. ª 2014 by the National Kidney Foundation, Inc.
INDEX WORDS: Hyponatremia; treatment; continuous venovenous hemofiltration (CVVH); hemodialysis.

INTRODUCTION
In patients with chronic severe symptomatic hyponatremia and concomitant kidney failure, hypertonic
saline should be used until resolution of the symptoms. Thereafter, the goal should be gradual correction of serum sodium level, by not more than
8-10 mEq/L over 24 hours.1 In those who require
hemodialysis, rapid correction of serum sodium concentration [Na1] could ensue and put the patient at
risk for osmotic demyelination syndrome.2,3 Management using continuous renal replacement therapy
also is challenging due to the lack of commercially
available hypotonic dialysate or replacement ﬂuids.
This teaching case presents a patient with acute kidney injury and severe hyponatremia (serum [Na1] ,
100 mEq/L) treated with continuous venovenous
hemoﬁltration (CVVH) in which gradual correction of
serum [Na1] was achieved using hypotonic replacement ﬂuid composed of successively higher [Na1].

CASE REPORT
Clinical History and Initial Laboratory Data
A 54-year-old woman presented to the emergency department
with confusion, decreased responsiveness, and generalized weakness for 24 hours. She had nausea and decreased oral intake for a
few weeks, with reduced urine output for a few days. Her medical
history was signiﬁcant for uncontrolled hypertension and alcohol
abuse. Blood pressure was 246/115 mm Hg, heart rate was
106 beats/min, respiration rate was 21 breaths/min, and pulse oximetry was 94% on room air.
The patient’s physical examination revealed bilateral basilar rales.
Serum laboratory studies showed the following values: sodium,
96 mEq/L; potassium, 5.6 mEq/L; chloride, 64 mEq/L; bicarbonate,
16 mEq/L; serum urea nitrogen, 51 mg/dL; creatinine, 9.9 mg/dL;
phosphorus, 8.1 mg/dL; serum osmolality, 226 mOsm/kg; and brain
natriuretic peptide, 2,800 pg/mL. Arterial blood gas analysis showed
pH 7.36, PaCO2 of 27.9 mm Hg, PaO2 of 57.5 mm Hg, and bicarbonate level of 15.4 mEq/L. Urine sediment showed few granular

casts. Urine osmolality was 157 mOsm/kg, sodium was 40 mEq/L,
and creatinine was 33 mg/dL, with fractional sodium excretion
of 12.5%.

Additional Investigations
Computed tomography of the brain demonstrated no intracranial
pathology. The radiograph of the chest showed mild to moderate
cardiomegaly with pulmonary vascular congestion.

Diagnosis
Acute kidney injury and severe hypervolemic hypotonic hyponatremia was diagnosed. Acute tubular necrosis was the presumptive cause of the acute kidney injury.

Clinical Follow-up
Treatment goals were identiﬁed to include gradual correction of
hyponatremia, alleviation of congestive heart failure, and management of hyperkalemia, azotemia, and hyperphosphatemia. The
patient began CVVH using a modiﬁed hypotonic replacement
ﬂuid. Standard ﬂuid bags (NxStage PureFlow dialysate solution
RFP 401; NxStage Medical Inc) were diluted by the addition
of pure water to 112 mEq/L at the start of CVVH, 120 mEq/L
24 hours later, and 128 mEq/L 56 hours after initiating CVVH.
CVVH was performed for a total of 72 hours at a rate of correction
recommended by therapeutic guidelines4 (Fig 1). Mentation
improved without neurologic sequelae. On hospital day 2, an
ultrasonogram showed bilateral hydronephrosis, which was treated
by bilateral nephrostomy tube insertions on day 4 that produced
complete recovery of kidney function. The patient was essentially
anuric (urine , 100 mL/d) until bilateral nephrostomy placement.
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Figure 1. Serum sodium concentrations at baseline and during continuous venovenous hemofiltration (CVVH) while using
successively higher replacement fluid concentrations. The r2 denotes the coefficient of determination between predicted and
measured serum sodium levels for each 24-hour CVVH period.

The ﬁnal diagnosis was obstructive acute kidney injury due to
cervical cancer.

DISCUSSION
Management of hypotonic hyponatremia should be
based on its presumed duration and severity. In acute
hyponatremia, free water movement into brain cells
results in varying degrees of cerebral edema.5 The
risk of electrolyte disturbance exceeds that of osmotic
demyelination syndrome secondary to rapid correction. Chronic hyponatremia is associated with brain
cells adaptively losing organic osmolytes, and thus
life-threatening cerebral edema is less likely.6 This
adaptation renders the brain vulnerable to osmotic
demyelination syndrome in response to a rapid increase in serum [Na1].7-9 Therefore, management of
hyponatremia entails balancing the risks of hyponatremia with those of rapid correction. For decades, a
total increase of 12 mEq/L per day was considered
safe10,11; however, osmotic demyelination syndrome
has been reported with correction of only 10 mEq/L
per day.12,13 Consequently, even lower limits of
correction have been recommended: 10 mEq/L in
24 hours and 18 mEq/L in 48 hours.1
Patients with severe hyponatremia and kidney
failure with volume expansion pose a unique therapeutic challenge. Hypertonic saline is undesirable in
patients with kidney failure and expanded volume
status. Similarly, V2 receptor antagonists are not
likely to be effective at reduced glomerular ﬁltration
rates because of diminished ﬂuid delivery to the distal
nephron14; in the absence of published experience at
reduced glomerular ﬁltration rates, the use of these
agents cannot be recommended.
Successful treatment of patients with kidney failure and hyponatremia using different extracorporeal
306

Figure 2. The expected serum sodium change during hemodialysis (HD), sustained low-efficiency dialysis (SLED), and
continuous venovenous hemofiltration (CVVH) with noncustomized fluid bags. For HD, treatment time is 3 hours, dialysate
sodium is 130 mEq/L, blood flow rate is 200 mL/min, and approximate delivered urea clearance is 180 mL/min (10.8 L/h). For
SLED, treatment time is 8 hours, dialysate sodium is
130 mEq/L, dialysate flow is 100 mL/min, blood flow rate
is 200 mL/min, and approximate delivered urea clearance is
78 mL/min (4.7 L/h). For CVVH, treatment time is 24 hours,
replacement fluid sodium is 140 mEq/L, blood flow rate is
300 mL/min, replacement fluid is 1.2 L/h, and approximate delivered urea clearance is 1.2 L/h.

modalities, including hemodialysis at low blood
ﬂow rates,15 CVVH,16 and continuous venovenous
hemodialysis,17,18 has been reported. However,
all renal replacement modalities could be deleterious when used in severe cases of hyponatremia
(Fig 2).
In patients with kidney failure and severe hyponatremia, hemodialysis would induce a rapid increase
in serum Na1 with the potential for osmotic demyelination syndrome.2,19 The high blood ﬂow rates
(Qb; . 200 mL/min) and inability to reduce the dialysate bath’s [Na1] to ,130 mEq/L are 2 reasons for
the high Na1 transfer when using conventional hemodialysis to treat hyponatremia. Theoretically, the
dialysis machine’s alarm system could be manipulated and calibrated to a lower [Na1], at the expense
of a treatment session with nonfunctional conductivity monitoring, posing an unwarranted and signiﬁcant
safety risk.
Complex Na1 kinetic models were shown to be
able to predict end-dialysis serum [Na1] in previous clinical studies.20 We present a simpler set of
Na1 kinetic equations that are more easily applicable in clinical practice and can be used to estimate serum [Na1] at the end of treatment. By
applying urea clearance principles to Na1 dialysance (D), serum [Na1] at the end of hemodialysis
and CVVH treatments is predictable. The ﬁnal
serum [Na1] is the sum of the initial serum [Na1]
Am J Kidney Dis. 2014;64(2):305-310
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Management of Severe Hyponatremia With CVVH
Box 1. CVVH With Fluid Customization


Determine target correction for the next 24 hours (not to exceed 10 mEq/L)





initial serum Na 1 5 98 mEq L; desired D serum Na 1 5 10 mEq=L



Determine minimum urea clearance (K) in L/h
Urea clearance for a 50-kg female: 25 mL/kg/h 3 50 kg 5 1.25 L/h



Determine delivered K for a fixed blood flow rate (Qb), replacement fluid (Qrf), and ultrafiltration rate (Quf)

  
L
Qb
5
3 ðQrf 1 Quf Þ
Urea clearance
h
Qb 1Qrf



Adjust replacement fluid rate for a fixed Qb and Quf to achieve a desired K
K 5 1.3 L/h with Qb 5 300 mL/min, Qrf 5 1.2 L/h, and Quf 5 167 mL/h




1

Assume Na dialysance (D) 5 K
To calculate delivered Dt/V over each 24-hour period, estimate total-body water (TBW) volume (V):
V z TBW 5 0.5* 3 estimated dry weight for females 1 estimated ECF expansion
V z TBW 5 0.6* 3 estimated dry weight for males 1 estimated ECF expansion



We estimated about 6 L of edema. Estimated dry weight z 44 kg and 6 L of edema 5 44 3 0.5 1 6 5 28 L.
Determine replacement fluid [Na1] needed to achieve desired [Na1] change
Replacement fluid ½Na 1  5

desired D serum ½Na 1 


1 initial serum ½Na 1 
D 3 24 h
12e 2 v
D 3 24 h




Declining V with ultrafiltration will have minimal impact on 1 2 e 2 v . If desired, an average of time 5 0 and time 5 24-hour
estimated V can be used to predict the replacement fluid with better accuracy.
It is w0.66 with an estimated V 5 28 L and 0.71 with an estimated V 5 24 L by the end of the first 24 hours. The average of the
2 values can be used when estimating the replacement fluid ½Na1 :
Refer to Table 1 or 2 to determine the volume of water to be added to replacement fluid or to be exchanged to achieve desired
replacement fluid ½Na1 :
In summary, in those in whom 24-hour Kt/V 5 1.2, we use fluid [Na1] about 10-12 mEq/L higher than the patient’s serum [Na1]
for daily correction of 6-8 mEq/L.

Abbreviations: CVVH, continuous venovenous hemofiltration; ECF, extracellular fluid; [Na1], sodium concentration.
*Multiply by 0.4 and 0.5 for elderly females and males, respectively.

and the change in serum [Na1] incurred during
dialysis (equation 1).




(1) Final serum Na1 5 initial serum Na1


1 D serum Na1
The change in serum [Na1] (ignoring ultraﬁltration) at time t is determined by a number of variables
(equation 2), including the initial serum [Na1], the
dialysate [Na1], total-body water volume (V),21
and D.




(2) D serum Na1 5 dialysate Na1


2initial serum Na1


Dt
3 12e2 v
An estimate of V can be calculated by using
Watson formula applied to the patient’s euvolemic
weight and adding any estimated edema volume.
Fixed-volume (as opposed to variable-volume) single-pool Na1 kinetic modeling can be used for
simplicity without compromising clinically sufﬁcient
accuracy. However, one also could use the average

of pre- and posttreatment V to better account for the
variable volume. Because Na1 and urea are both
non–protein-bound small solutes and have similar
effective blood water ﬂow, their dialyzer solute
transfer characteristics would be similar. Therefore,
effective urea clearance can be used to estimate D.22
An estimate for urea clearance could be obtained
from nomograms that display the relationship of
blood water urea clearance as a function of dialyzer
efﬁciency, Qb, and dialysate ﬂow rate. Our patient
had a predialysis body weight of 50 kg. We estimated that she had an approximate V of approximately 26-27 L. Predialysis serum [Na1] was
98 mEq/L. Hemodialysis treatment for 3 hours with
130-mEq/L dialysate [Na1], 1.6-m2 surface area
hemodialyzer, 180-minute treatment time, 500-mL/
min dialysate ﬂow rate, and 200-mL/min Qb would
have achieved an approximate single-pool Na1 Dt/V
of 1.2. This should result in change in serum [Na1]
of 22 mEq/L by the end of the 3-hour treatment, or
change in serum [Na1] of w7 mEq/h, and would
have put the patient at risk for osmotic demyelination syndrome.
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The change in serum [Na1] using sustained lowefﬁciency dialysis (SLED) also can be estimated using equation 2. For example, at Qb of 200 mL/min,
dialysate [Na1] of 130 mEq/L, and dialysate ﬂow rate
of 100 mL/min, D would be at least 80 mL/min,
somewhat lower than the dialysate ﬂow due to dialysate shunting and channeling on the dialyzer.
Nevertheless, an 8-hour SLED treatment would still
result in a 24-mEq/L increase in serum [Na1] with an
adequate urea Kt/V of 1.4. The previous equations
ignore the Gibbs-Donnan effect on Na1 kinetics, the
impact of possible access recirculation, and nonisotonic intravenous ﬂuid, Na1, or potassium
administration to the patient, yet demonstrate the
limitations and dangers posed by hemodialysis and
SLED in severe hyponatremia.
Alternatively, by using CVVH, the serum [Na1]
correction rate can be controlled by making successive dilutions of the replacement ﬂuid bags
every 24 hours. Simply, the [Na1] of the replacement ﬂuid needs to be about 3-4 mEq/L higher
than the desired goal serum [Na1] while delivering
a urea Kt/V of 1.2 every 24 hours. Through kinetic
modeling of D, we can estimate the concentration
of the replacement ﬂuid required every 24 hours to
achieve a speciﬁc desired change. Importantly, the
purely convective Na1 kinetics in CVVH allows us
to predict D accurately, even without online clearance tools. The replacement ﬂuid [Na1] is determined by the desired change in serum [Na1] in 24
hours, the D, the duration of treatment, and the V,
which has to be adjusted every 24 hours to account
for changing total-body weight. To account for the
variable volume, the mean value of the estimated
initial and ﬁnal volume could be used as an estimate of V:

 desired D serum ½Na1 


(3) Replacement fluid Na1 5
D 3 24 h
12e2 v


1 initial serum Na1

D in predilution CVVH mode is determined by
replacement ﬂuid ﬂow rate (Qrf); ultraﬁltration rate
(Quf); effective blood water ﬂow for Na1, which is
about equal to Qb; and the Na1 sieving coefﬁcient
(SNa1), which is almost equal to 1:



Qb
(4) D 5
3 SNa1 3 Qrf 1 Quf
Qb 1Qrf
For our patient, the goal for the ﬁrst 24 hours was
to increase serum [Na1] by 10-12 mEq/L to
108 mEq/L because we assumed an element of acute
hyponatremia in the presence of mental status
changes and pulmonary edema, and to perform 4-L
Quf. To estimate the replacement ﬂuid [Na1]
needed, we ﬁrst had to estimate D using equation 4.
We selected ﬂows to deliver w25 mL/kg per hour or
1.2 Kt/V per day urea clearance for adequacy and
perform 4-L ultraﬁltration. The estimated D was
1.28 L/h at Qb of 300 mL/min, Qrf of 1.2 L/h,
and Quf of 167 mL/h. For a desired change of
10 mEq/L and an initial serum [Na1] of 98 mEq/L,
the estimated replacement ﬂuid [Na1] using
equation 3 was 112 mEq/L. The replacement ﬂuid
used achieved the desired serum [Na1] target of
108 mEq/L at the end of 24 hours. Our goal for the
second 24 hours was to increase serum [Na1] to
w116 mEq/L and perform 2-L ultraﬁltration. We
adjusted the replacement ﬂuid Na1 to 120 mEq/L to
achieve serum [Na1] of 116 mEq/L after the second
24 hours. Using equations 1 and 2, the predicted
serum [Na1] after 24 hours was 116.8 mEq/L using
an estimated clearance of 1.2 Kt/V with V of 23 L.
Serum [Na1] increased to 118 mEq/L by the end of
treatment. This was slightly higher than estimated
by the equations, which might be explained in part
by intravenous medications suspended in normal
saline solution (total, 500 mL). The patient’s mentation and responsiveness improved, and CVVH
was withheld and then reinitiated after 8 hours at a
serum [Na1] of 120 mEq/L with the goal to remain
at ,126 mEq/L over the next 24 hours. Using

Table 1. Effect of Adding Different Volumes of Water to 5-L Replacement Fluid Bag
Volume Added
(mL)

0
250
429
500
713
750
1,000
1,250

Sodium Final
(mEq/L)

Potassium Final
(mEq/L)

Bicarbonate Final
(mEq/L)

Calcium Final
(mEq/L)

Magnesium Final
(mEq/L)

Chloride Final
(mEq/L)

140.00
133.33
128.94
127.27
122.53
121.74
116.67
112.00

4.00
3.81
3.68
3.64
3.50
3.48
3.33
3.20

34.00
32.38
31.31
30.91
29.76
29.57
28.33
27.20

3.00
2.86
2.76
2.73
2.63
2.61
2.50
2.40

1.00
0.95
0.92
0.91
0.88
0.87
0.83
0.80

113.00
107.62
104.07
102.73
98.90
98.26
94.17
90.40

Note: The 5-L replacement fluid bag is NxStage PureFlow dialysate solutions RFP 401.
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Table 2. Effect of Exchanging Different Volumes of a 5-L Replacement Fluid Bag With Sterile Water
Volume Replaced
(mL)

0
250
429
500
713
750
1,000
1,250

Sodium Final
(mEq/L)

Potassium Final
(mEq/L)

Bicarbonate Final
(mEq/L)

Calcium Final
(mEq/L)

Magnesium Final
(mEq/L)

Chloride Final
(mEq/L)

140.00
133.00
127.99
126.00
120.04
119.00
112.00
105.00

4.00
3.80
3.66
3.60
3.43
3.40
3.20
3.00

32.00
30.40
29.25
28.80
27.44
27.20
25.60
24.00

3.00
2.85
2.74
2.70
2.57
2.55
2.40
2.25

1.00
0.95
0.91
0.90
0.86
0.85
0.80
0.75

113.00
107.35
103.30
101.70
96.89
96.05
90.40
84.75

Note: The 5-L replacement fluid bag is NxStage PureFlow dialysate solution RFP 401.

replacement ﬂuid Na1 of 128 mEq/L, serum [Na1]
increased to 126 mEq/L. A suggested management
outline is summarized in Box 1.
A stepwise correction of the patient’s serum [Na1]
should be performed using hypotonic replacement
ﬂuid, with successively higher [Na1] adjusted at least
every 24 hours. The replacement ﬂuid’s [Na1] could
be reduced by adding sterile water to standard
replacement ﬂuid bags. Alternatively, sterile distilled
water could be exchanged for a volume of replacement ﬂuid. The effect of sterile water added or
exchanged on Na1 and other electrolyte concentrations is demonstrated in Tables 1 and 2. The volume
of sterile water to be added to a replacement ﬂuid
(RF) bag to achieve a desired [Na1] can be given by
the equation:

RF volume 3ðinitial RF ½Na1  2 desired RF ½Na1 Þ
desired RF ½Na1 

The use of the former method was not preferred in
this case because the large volume of sterile water
(1.25 L) required to dilute the standard 5-L NxStage
PureFlow dialysate solution to 112 mEq/L would not
ﬁt in the manufacturer’s bag. We chose to exchange
sterile distilled water for a volume of replacement
ﬂuid. The volume to be exchanged was calculated
using the following formula:
Volume to exchange
5 RF volume 2

Volume to exchange 5 5 L 2

112 mEq=L 3 5 L
51L
140 mEq=L

Similarly, the volume exchanged with sterile distilled
water to achieve replacement ﬂuid [Na1] of 120 and
128 mEq/L would be 714 and 429 mL, respectively.
If serum [Na1] increases by .3 mEq/L in any
6 hours, the CVVH prescription may be adjusted to
not exceed daily urea Kt/V of 1.2 or urea clearance of
25 mL/kg per hour, or replacement ﬂuid bags with
lower [Na1] may be used. Finally, in an emergency,
5% dextrose in water may be administered intravenously to lower serum [Na1].
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